WORCESTER, Mass.--(BUSINESS WIRE)--Dec. 1, 2005--Biovest International (OTCBB:BVTI), a biopharmaceutical company focused on the development of patient specific immunotherapeutics and automated cell culture instrumentation, announced that an abstract being presented on December 11 at the American Society for Hematology in Atlanta, Ga., presenting long term follow-up data from its BiovaxID Phase 2 clinical trial is available on-line at http://www.hematology.org.
